Background
==========

Peri-prosthetic joint infection (PJI) is one of the most complex and debilitating complications of total joint replacement, which is the first and third major cause of revision following total knee arthroplasty and total hip arthroplasty, respectively \[[@b1-medscimonit-24-5549]--[@b4-medscimonit-24-5549]\]. *Staphylococcus* species are major pathogens, accounting for 50%--60% of all isolates \[[@b5-medscimonit-24-5549],[@b6-medscimonit-24-5549]\].

Fungal PJI is rare and occurs in approximately 1% of all PJI \[[@b7-medscimonit-24-5549],[@b8-medscimonit-24-5549]\], representing a diagnostic and therapeutic challenge because of a lack of established guidelines \[[@b7-medscimonit-24-5549]\]. Chronic infections are typically treated in North America with a two-stage exchange protocol. Numerous studies have reported that two-stage revision surgery and articulating spacers can result in a rate of infection control as high as 95% in patients with PJI \[[@b9-medscimonit-24-5549]--[@b12-medscimonit-24-5549]\], but whether this protocol is efficacious for fungal PJI remains controversial. Hwang et al. reported on 30 two-stage revision procedures for fungal PJI, and only 2 knees became reinfected at the last follow-up date \[[@b13-medscimonit-24-5549]\]. Garcia-Oltra et al. concluded that treatment with fluconazole and debridement or two-stage replacement with a spacer was associated with a high failure rate \[[@b14-medscimonit-24-5549]\].

In 2002, McPherson et al. reported the first clinical staging system for PJI, which can divide patients into different gradations according to infection type, host status, and extremity status \[[@b15-medscimonit-24-5549]\]. This staging system is helpful in evaluating fungal PJI and treatment algorithms.

The purpose of the present retrospective study was: (1) to determine the success rate of 2-stage exchange arthroplasty based on the patients' grades according to McPherson's staging system and (2) to assess which factors are associated with failure of treatment.

Material and Methods
====================

Following Institutional Review Board approval, from January 2000 to June 2015, we retrospectively reviewed 18 joints (13 knees and 5 hips) of 17 patients (10 women and 7 men) who were identified infection by fungal at our institute. One of the female patients had infected bilateral knees. The average age of diagnosis was 61.2 (range, 42--78) years, and the mean follow-up was 65.1 months (range, 25--129 months). We defined fungal PJI as positive culture tests of 2 or more samples from joint aspiration or intraoperative specimens. The fungi were incubated on TTC-Sabourand's medium.

The following information was collected through medical records and telephone follow-up: age, sex, body mass index (BMI), site of infection, pathogenic fungi, other microorganisms cultured, laboratory values (CRP and ESR), operative method, local and system antifungal agents, interval between prosthesis resection and reimplantation, prior operation times, time from primary total joint arthroplasty to the diagnosis of fungal PJI, comorbidity and grade of each patient according to McPherson's staging system, final outcomes and patients' satisfaction, and duration of follow-up ([Table 1](#t1-medscimonit-24-5549){ref-type="table"}).

We treated all the patients with the two-stage protocol. After removal of all components of the infected joint, a thorough debridement was performed. Subsequently, we implanted antibiotic-loaded bone cement spacers and systemically administered antifungal agents. An articulating spacer was applied for 12 knees and 4 hips, and only 2 irrigated static spacers were used. The antibiotic type and doses added in bone cement were used at the discretion of the operating surgeon. Only 8 spacers contained antifungal agents and Vancomycin because of specific species isolated through preoperative aspiration, and 2 of these spacers were irrigated static spacers. A total of 9 patients had negative culture results at preoperative aspiration and used Vancomycin-loaded bone cement spacer. One of the patients had resected components and implanted spacer performed at an outside institute; thus, whether antibiotic-loaded or not in the spacer was unknown ([Table 2](#t2-medscimonit-24-5549){ref-type="table"}). Intraoperative synovial fluid and suspicious tissue specimens were collected for microbiological culture (aerobic, anaerobic, *Mycobacterium*, and fungal) and pathological examination. Subsequently, patients received parenteral antifungal agents according to sensitivity test of the culture for at least 6 weeks, and most of them were followed by oral fluconazole or rifampicin. Reimplantation was controlled until antifungal agents were paused for at least 2 weeks and inflammatory markers, such as ESR and CRP, declined to normal.

We defined treatment success as successful reimplantation without "persistent infection" or "reinfection" during the follow-up. Treatment failure was defined as the occurrence of any of the following conditions at any time after the initial surgical procedure: (1) peri-prosthetic joint infections attributed to the presence of the original microorganism (relapse of infection) or a different strain (reinfection); (2) development of a sinus tract; or (3) death related to the peri-prosthetic joint infection \[[@b16-medscimonit-24-5549]\]. According to McPherson's staging system, we grouped type A, based on host risk factors, into a low-risk group, and types B and C into a high-risk group.

The descriptive statistics are reported as the number (percentage) or mean (range), as appropriate. We compared binary variables by chi-square and Fisher exact tests. A paired *t* test was used to compare the differences between preoperative and postoperative HSS/Harris scores, as well as range of motion (ROM). Analyses were performed using SPSS software (Version 19.0; SPSS Inc., Chicago, IL, USA).

Results
=======

Clinical features
-----------------

A total of 10 patients (11 knees) had the symptom of pain and swelling: some patients felt warmth and redness locally, 5 patients (2 knees and 3 hips) had sinus tract, and 1 patient knee had internal instability. The range of motion (ROM) of the 12 knees (1 patient resected arthroplasty at another hospital), prior to the resection of arthroplasty, was 82 degrees. According to McPherson's classification, 2 patients (3 knees) belonged to IIIA1, 10 patients were categorized as IIIA2, IIIA3, IIIB1, IIIB2, or IIIC2, and 1 patient was categorized as IIIC3. The mean symptom duration was 20.7 months (range, 1--84 months).

Microbiology and laboratory findings
------------------------------------

In total, 15 patients (1 patient had a bilateral knee infection) were infected with *Candida*, and 6 (6 knees) patients showed *Candida* parapsilosis, which contained 3 mixed infections: *Candida tropicalis*, human *Staphylococcus* and *Staphylococcus epidermidis,* and *Pseudomonas aeruginosa*. In 5 patients, the causative organism identified was *Candida albicans*; however, 4 patients showed a mixture of other episodes, including *Staphylococcus cohnii*, *Acinetobacter lwoffi*, *Staphylococcus aureus*, and *Enterococcus faecalis*. Two patients had *Candida glabrata* infections, and one of these patients was simultaneously infected with Gram-negative bacilli. Another 2 patients had *Candida freyschussii* and *Candida tropicalis* infections, and one of these patients showed a mixed infection with *Staphylococcus epidermidis* and *Escherichia coli*. Molds were isolated in 3 patients, including *Aspergillus* in 2 patients, and one of these patients was coinfected with Gram-positive bacteria and rapid *Mycobacterium*, while the other patient was infected *Acremonium striatum*. Prior to resection of the prosthesis, ESR and CRP was detected in 16 patients (11 knees and 5 hips), and the average value of CRP and ESR was 4.4 mg/dL (range, 0.3--11.9 mg/dL) and 57.5 mm/h (range, 17--130 mm/h), respectively. IL-6 was detected in 7 patients (7 knees and 1 hip), and the mean level at presentation was 12.77 pg/ml (range, 2--41.63 pg/ml).

Surgical treatment
------------------

Five patients underwent irrigation and debridement (ID) with prosthesis reservation; however, because of uncontrolled infection, all of these patients had components removed subsequently. The other 13 patients (8 knees and 5 hips) had resected prosthesis at the initial surgery. Thus, 18 spacers were inserted in total. According to preoperative aspiration, 8 patients received antifungal-loaded spacers because of positive fungal cultures, whereas another 9 patients (4 knees and 5 hips) received Vancomycin-loaded or other antibacterial-loaded spacers. Additionally, 2 irrigated static spacers were implanted, and we irrigated with fluconazole and Vancomycin for 4 weeks. One patient underwent index surgery at another institution, and whether antibacterial agents were added in bone cement is unknown.

### Antifungal therapy

Most of the patients were subjected to 6 weeks systemic antimicrobial therapy after the spacer implantation. Except for 1 patient, who was administered Vancomycin for 2 weeks after resection arthroplasty, and whose preoperative samples cultured Gram-positive bacteria, the remaining patients were administered antifungal agents. Fluconazole was intravenously injected into 15 patients (10 knees and 5 hips) for a minimum of 2--24 weeks, 12 patients (8 knees and 4 hips) subsequently received oral fluconazole or Itraconazole for 6--14 weeks, and 4 patients received combined Vancomycin and/or Rifampicin for 6 weeks for the coexist bacteria. Voriconazole was parenterally administered to 2 patients for 6 weeks, followed by oral fluconazole treatment for 12 weeks.

After the systemic administration of antifungal agents, ESR and CRP values were measured until they declined to normal prior to reimplantation; otherwise, the procedure was not conducted. The median duration of resection arthroplasty and reimplantation was 33.9 weeks (range, 12--132 weeks). A total of 14 patients (11 knees and 3 hips) underwent prosthesis reimplantation, and 13 patients (10 knees and 3 hips) ultimately showed success, while 1 patient experienced recurrent infection after successful reimplantation. The patients were subjected to further debridement and exchanged tibial-bearing inserts. One patient had spacer resection and no reimplantation at last follow-up. However, 3 patients (2 knees and 1 hip) underwent irrigation and debridement, and the spacer was exchanged again due to recurrent or persistent infection ([Figure 1](#f1-medscimonit-24-5549){ref-type="fig"}). Delayed reimplantation was performed in one of the 3 patients, while another patient did not have the prosthesis changed because of the financial burden, and the other patient had the spacer changed a third time due to recurrent infection.

Risk factors
------------

According to the univariate analysis, patients who have more than 1 risk factor of host and extremity are more likely to fail (15.4% *vs.* 40%, P=0.53, 69.2% *vs.* 100%, P=0.278) ([Table 3](#t3-medscimonit-24-5549){ref-type="table"}) but the difference was not significant. In the treatment failure group, patients had a longer interval between prosthesis resection and reimplantation (mean, 69 weeks; range, 16--132 weeks) than in the success group (mean, 23.1 weeks; range, 12--40 weeks) (P=0.240). The mixed infection rate was 80% in the treatment failure group and 46.2% in the success group (P=0.314). However, we did not find any significant difference between individuals with diabetes mellitus and hypertension and heart disease comorbidities and individuals who did not have these diseases. Thus, debridement history, infection site, and presence of sinus tract may not be treatment failure risk factors.

Outcome
-------

At the time of follow-up at a mean of 65.1 months (range, 25--129 months) after 2-stage reimplantation, 13 (10 knees and 3 hips, 72.2%) of the 18 joints (13 knees and 5 hips) did not experience recurrent or persistent infection, 5 (3 knees and 2 hips, 27.8%) of the 18 joints (13 knees and 5 hips) failed to control infection after reimplantation prosthesis or spacer, and all patients underwent further surgical intervention. No patients had signs of infection at the latest follow-up, and no above-the-knee amputation, arthrodesis, or resection of arthroplasty occurred. The failure rate was 21.4% in the low-risk group and 50% in the high-risk group. The HSS/Harris score increased from 50.8/47 (range, 35--68) to 81.1/81.8 (range, 51--92), and the range of motion (ROM) improved from 82.1° (range, 45°--135°) to 89.2° (range, 0°--120°). A total of 14 patients (11 knees and 3 hips, 77.8%) were satisfied with the revision outcome.

Complications
-------------

There was no dislocation or fracture of the bone cement spacer. Two patients had leukopenia after using antifungal agents, and 1 of these patients also had renal insufficiency and peri-prosthetic fracture. At the latest follow-up, 1 patient had an unexplained abnormal sound.

Discussion
==========

Fungal PJI is a rare entity that occurs in approximately 1% of all PJI. With increasing numbers of total knee arthroplasties (TKA) and total hip arthroplasties (THA) being performed, the incidence of fungal PJI may be increasing \[[@b7-medscimonit-24-5549],[@b8-medscimonit-24-5549],[@b13-medscimonit-24-5549],[@b17-medscimonit-24-5549],[@b18-medscimonit-24-5549]\]. Additionally, the therapeutic and diagnostic guidelines for fungal PJI have not been established, posing a challenge to the orthopedic surgeon. McPherson et al. constructed a classification system based on infection type, host status, and extremity risk factors \[[@b15-medscimonit-24-5549]\], and to the best of our knowledge, there are no published reports concerning the fungal PJI success rate on the basis of this classification system. We defined the results of 2-stage revision for fungal PJI according to McPherson's staging system.

Most fungal PJIs are chronic infections, rarely accompanied by acute symptoms due to the indolent character of fungi. All patients in our hospital were classified as late chronic infection (type III), and most had pain and swelling, with or without warmth and redness. These common infection symptoms were found to be statistically insignificant in previous reports \[[@b19-medscimonit-24-5549],[@b20-medscimonit-24-5549]\]. In the present study, the median duration of symptoms was 20.8 months (range, 1--84 months), consistent with results reported by Brooks (median, 14 months) \[[@b18-medscimonit-24-5549]\] and Hwang (median, 19.6 months) \[[@b13-medscimonit-24-5549]\], but shorter than the findings reported by Azzam (median, 29 months) \[[@b7-medscimonit-24-5549]\] and Cobo et al. (median, 33 months) \[[@b17-medscimonit-24-5549]\]. This finding may be related to their intrinsic aggressiveness, as fungal infections are indolent and do not likely account for the observed symptoms.

In contrast to most of the fungal infection caused by *Candida albicans* \[[@b17-medscimonit-24-5549]\], *Candida parapsilosis* was the major pathogen in the present study, consistent with Hwang and Wang \[[@b13-medscimonit-24-5549],[@b21-medscimonit-24-5549]\]. However, 10 patients (5 knees and 5 hips) also had other fungal or bacterial infections, which may be incubated from preoperative joint aspiration or intraoperative samples. There is no standard definition of PJI, and the Infectious Disease Society of America (IDSA) and the Musculoskeletal Infection Society (MSIS) \[[@b22-medscimonit-24-5549],[@b23-medscimonit-24-5549]\] use 2 different definitions. Therefore, considering the complexity of fungi, extending the incubation time is necessary for suspicious infections. Furthermore, more than 4 samples were recommended for seeding onto 3 different culture media \[[@b24-medscimonit-24-5549]\].

Debridement with the retention of the prosthesis is not an ideal treatment protocol. Although previous studies \[[@b18-medscimonit-24-5549],[@b25-medscimonit-24-5549]\] have reported the effectiveness of this procedure, these infections were treated in acute type patients and the studies had small sample sizes. Debridement with the retention of the prosthesis was successful in 4 of the 22 patients examined \[[@b26-medscimonit-24-5549]\]. The 4 patients who underwent initial surgical procedure by debridement with retention of the prosthesis all failed \[[@b13-medscimonit-24-5549]\], which is similar to the outcome in the present study. Only 1 report described 1-stage exchange arthroplasty \[[@b27-medscimonit-24-5549]\]; therefore, we cannot draw any conclusion from a case report. Although Garcia-Oltra et al. concluded that treatment with fluconazole and debridement or 2-stage replacement with a spacer was associated with a high failure rate \[[@b14-medscimonit-24-5549]\], and resection arthroplasty and 2-stage revision were recommended to eradicate infection \[[@b7-medscimonit-24-5549],[@b13-medscimonit-24-5549],[@b16-medscimonit-24-5549],[@b21-medscimonit-24-5549],[@b26-medscimonit-24-5549],[@b28-medscimonit-24-5549]\], the present study achieved an acceptable success rate (13/18). However, a surgeon should make the decision according to the condition of each patient. In high-risk group type C, consisting of individuals whose host risk factors were more than 2, all patients failed and had to undergo further debridement and prolonged use of antifungal agents.

Antibiotic-loaded bone cement spacers are now considered the criterion standard for the treatment of bacterial PJI \[[@b29-medscimonit-24-5549]\]. However, whether this method is efficacious in the treatment of fungal PJI is controversial, especially for the type and dose of antifungal agents added to the bone cement. Amphotericin B has the advantage of being heat-stable and available in powder form, and has been reported to successfully treat fungal PJI \[[@b30-medscimonit-24-5549]\]. However, it has also been reported to be difficult to elute from bone cement spacer \[[@b31-medscimonit-24-5549]\]. In the present study, Vancomycin and Amphotericin B/Voriconazole were mixed into bone cement because of the high incidence of combined fungal and bacterial infection (33%) \[[@b7-medscimonit-24-5549]\]. The minimum mixing ratio is 2 g of Vancomycin and 1 g of Amphotericin B in 120 g of bone cement (2.5%, Palacios MV+G), and the maximum mixing ratio is 8 g of Vancomycin, 2.5 g of Amphotericin B, and 1 g of Voriconazole in 80 g of bone cement (14.4%). In the success group, there were 5 joints that were mixed with antifungal agents in the spacer or their first spacer (5/12). In contrast, in the failure group, there were 2 joints that were mixed with antifungal agents in the spacer or their first spacer (3/5). (41.6% *vs.* 60%, P=0.620, [Table 3](#t3-medscimonit-24-5549){ref-type="table"}). Mixing with antifungal agents may not help increase the success rate. No spacer fracture occurred prior to reimplantation, suggesting that the bone cement spacer mechanical character is not be affected by Vancomycin, Amphotericin B, or Voriconazole.

System antifungal agent administration is of vital importance to controlling fungal infections. Amphotericin B and fluconazole were reported to be effective in a previous study \[[@b32-medscimonit-24-5549],[@b33-medscimonit-24-5549]\]. However, the duration of antifungal agents has not been established. The Infectious Diseases Society of America (IDSA) recommends treatment with Amphotericin B or fluconazole for at least 6 weeks after the removal of the arthroplasty in most patients with fungal PJI \[[@b23-medscimonit-24-5549]\]. In the present study, most of the patients were administered intravenous fluconazole, Voriconazole, or Caspofungin for at least 6 weeks, with or without subsequent oral fluconazole treatment. The mean duration of oral fluconazole was 6.8 weeks (range, 0--20 weeks). In addition to fungal infection, 10 patients had infections mixed with other bacteria; therefore, sensitive antibiotics against bacteria were used. We do not recommend the use of other antibiotics in the absence of a specific bacterial infection. A long period of oral antifungal treatment has been recognized as an essential factor for the success of staged reimplantation after a fungal PJI \[[@b8-medscimonit-24-5549]\]. However, the previous report compared 6 weeks with 3 months of antifungal treatment, in which antibiotic treatment does not influence the outcome after reimplantation. We suggest that 6 weeks parenteral antifungal agents are necessary, and 6 subsequent weeks of oral antifungal treatment is also important. Additionally, blood testing is required, and liver and kidney function should be regularly monitored, as 2 patients in our study had leukopenia after using of antifungal agents, and 1 of these patients also suffered renal insufficiency.

Several risk factors have been associated with fungal infection. Host factors include diabetes diseases, an immunosuppressive or immunodeficient status, rheumatoid arthritis, malignancy, tuberculosis, and renal transplantation or insufficiency \[[@b7-medscimonit-24-5549],[@b28-medscimonit-24-5549],[@b34-medscimonit-24-5549]\]. In addition, immune and nutritional status can also determine the outcome \[[@b7-medscimonit-24-5549]\]. However, in the present study, we did not find significant risk factors based on these. According to the univariate analysis, patients who have more than 1 risk factor of host and extremity were more likely to fail (15.4% *vs.* 40%, P=0.53, 69.2% *vs.* 100%, P=0.278) ([Table 3](#t3-medscimonit-24-5549){ref-type="table"}). Although we did not find a statistically significant difference based in the present study, the higher failure rate in Host B/C and Extremity 2 indicated that worse host and extremity status may be associated with treatment failure, which needs further study and larger samples for confirmation.

The present study has several limitations. Firstly, the sample size was small, and only 17 patients (18 joints) were identified; thus, the strength of the data may be weakened. Secondly, because of a lack of guidelines concerning fungal diagnosis and treatment, different surgeons have different methods, especially in surgical treatment, antifungal regimens, antifungal agents loaded-in bone cement, and the interval between resection arthroplasty and reimplantation, we cannot provide a specific suggestion based on our research. Thirdly, due to the rarity of fungal infection, a randomized controlled study is difficult to perform, and the present retrospective study may have recall bias.

Conclusions
===========

In conclusion, debridement with the retention of the prosthesis is not an ideal treatment protocol for fungal PJI, and 2-stage revision could be efficient. We suggest that 6 weeks of parenteral antifungal agents are necessary, followed by 6 weeks of oral antifungal treatment. We do not recommend performing the 2-stage revision in patients with more than 2 host risk factors.
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###### 

Summary of 17 patients (18 joints) demographic data.

  Patient   Age/Sex   BMI (kg/m^2^)   Joint   Pathogen Organism                                                            A1    Comorbidity                                                Mcpherson classification   A2   CRP at presentation (mg/l)   ESR at presentation (mm/h)   IL-6    HSS/Harris   ROM (°)
  --------- --------- --------------- ------- ---------------------------------------------------------------------------- ----- ---------------------------------------------------------- -------------------------- ---- ---------------------------- ---------------------------- ------- ------------ ---------
  1         63/F      28.9            Knee    *Aspergillus* spp.                                                           26    None                                                       A3                         3    4.99                         25                           3.87    40           45
  2         78/F      18.6            Knee    *Candida tropicalis, Candida parapsilosis*                                   12    None                                                       A2                         3    0.317                        29                           \<2.0   48           60
  3         63/F      23.8            Knee    *Candida albicans*                                                           10    Hypertension, diabetes, Rheumatoid                         C2                         1    0.317                        54                           6.84    61           70
  4         58/F      31.3            Knee    *Candida freyschussii*                                                       12    None                                                       A2                         2    0.95                         75                           --      35           50
  5         63/M      34.2            Knee    Gram-positivebacteria, Rapid mycobacterium, *Aspergillus*                    1.5   Hypertension, diabetes, Respiratory sleep pause syndrome   C3                         2    10                           92                           --      58           85
  6         52/F      24.8            Knee    *Acremonium strictum*                                                        42    None                                                       A2                         1    0.348                        17                           8.46    68           80
  7         64/M      22.5            Knee    *Candida glabrata*                                                           14    Coronary heart disease                                     A2                         2    --                           --                           --      42           45
  8         63/F      24              Knee    *Candida parapsilosis*                                                       29    Coronary heart disease                                     A1                         1    0.699                        90                           10.81   53           135
  9         63/F      24              Knee    *Candida parapsilosis*                                                       29    Coronary heart disease                                     A1                         1    0.699                        90                           10.81   52           125
  10        54/M      28.7            Knee    *Candida parapsilosis, Human Staphylococcus*                                 5     None                                                       A2                         2    7.49                         25                           41.63   48           130
  11        67/M      24              Knee    *Candida parapsilosis*                                                       5     Hypertension                                               A2                         2    0.48                         20                           --      55           100
  12        69/F      22.6            Knee    *Candida albicans, Staphylococcus cohnii*                                    3     Hypertension, diabetes                                     B1                         2    --                           --                           --      --           --
  13        66/M      29.41           Knee    *Candida parapsilosis, Staphylococcus epidermidis, Pseudomonas aeruginosa*   46    None                                                       A1                         2    1.65                         21                           --      49           60
  14        62/F      22.31           Hip     *Candida tropicalis, Staphylococcus epidermidis, Escherichia coli*           36    None                                                       A2                         3    9.11                         38                           --      62           --
  15        42/M      24.7            Hip     *Candida albicans, Acinetobacter lwoffii*                                    10    None                                                       A2                         2    11.9                         130                          --      48           
  16        53/F      16.6            Hip     *Candida albicans, Staphylococcus aureus*                                    8     Diabetes                                                   B2                         6    6.23                         61                           --      45           
  17        43/F      18.3            Hip     *Candida albicans, Enterococcus faecalis*                                    84    Gallbladder excision                                       A2                         4    6.3                          86                           --      43           
  18        78/M      25.6            Hip     *Candida glabrata,* Gram negative bacilli                                    1     None                                                       A2                         4    6.02                         67                           --      37           

The value of ESR, CRP, HSS, ROM was measured before arthroplasty resection. "−" -- unknown. Number of prior operation before resection arthroplasty include the first total joint arthroplasty and irrigation and debridement times before resection arthroplasty. A1 -- Symptom duration, time from symptom appearance to prosthesis resection (months). A2 -- No. of prior operation before resection arthroplasty

###### 

Treatment and outcome of 17 patients (18 joints) with fungal PJI.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient   Operative procedures                                     Time between stage (w)                                        Systemic antimicrobial therapy (w, before reimplantation)                                Systemic antimicrobial therapy (w, after reimplantation)    Impregnation of bone cement                                                               Complication     Follow-up (months)   HSS/ Harris   ROM (°)   Satisfaction     Outcome
  --------- -------------------------------------------------------- ------------------------------------------------------------- ---------------------------------------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------------------------------------- ---------------- -------------------- ------------- --------- ---------------- ---------
  1         Two-stage                                                28                                                            I.V. F 24w                                                                               I.V. F 4w + Oral R 6w                                       V1 6 g + M 2g +BC 80 g                                                                    None             62+18                91            90        Very satisfied   success

  2         Two-stage                                                12                                                            I.V. F 6w + V1 6w +Oral R 12w                                                            I.V. F 6w + V1 6w +Oral R 8w                                V1 4 g + M 2 g + V2 0.8 g + BC 80 g                                                       Leukopenia       28                   87            120       Very satisfied   success

  3         Two-stage exchange spacer                                64 ([\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}1)\   [\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}1: I.V. V2 6w + Oral F 12w\                                                                      [\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}1: V1 2 g + A1 1g + BC 120 g\         None             26                   60            0         satisfied        failure
                                                                     68 ([\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}2)    [\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}2: I.V. V2 4w + Oral F 8w                                                                        [\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}2: V1 4 g + V2 3 g + BC 120 g                                                                                        

  4         Two-stage                                                12                                                            I.V. F 6w+ Oral F 6w                                                                     I.V. C1 4w+ Oral F 8w                                       V1 12 g + BC 120 g                                                                        1^\*^            56+18                91            30        satisfied        success

  5         Debridement and Four-stage exchange arthroplasty         12 ([\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}1)\   [\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}1: I.V. V1 2w\                       I.V. F 4w                                                   [\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}1: V1 15 g + BC 80 g\                 None             51                   91            120       Very satisfied   failure
                                                                     28 ([\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}2)\   [\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}2: I.V. A2 8w+ Oral C2 4w + A3 4w\                                                               [\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}2: M8 g + A3 8g + A2 1 g + BC 80 g\                                                                                  
                                                                     16 ([\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}3)    [\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}3: I.V. F 8 weeks                                                                                [\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}3: M 4 g + BC 80 g                                                                                                   

  6         Debridement and Two-stage                                36                                                            I.V. V2 6w +Oral F 12w                                                                   I.V. V2 2w + Oral F 6w                                      V1 4 g + M 3 g + V2 0.4 g + BC 120 g                                                      None             30                   60            90        Not satisfied    success

  7         Debridement and Two-stage                                40                                                            I.V. F 6w + V1 6w + Oral I 12w                                                           I.V. F 1w                                                   F 4 weeks + V1 4w (Irrigation)                                                            None             129                  91            90        Very satisfied   success

  8         Two-stage                                                12                                                            I.V. F 6w +Oral F 6w                                                                     I.V.F 2w +Oral F 8w                                         V1 12 g + BC 80 g                                                                         None             44                   87            120       satisfied        success

  9         Two-stage                                                24                                                            I.V. F 8w +Oral F 14w                                                                                                                                V1 12 g + BC 80 g                                                                         None             44                   84            110       satisfied        success

  10        Debridement and Two-stage                                16                                                            I.V. F 6w +Oral F 6w                                                                     I.V. V2 6w + Oral F 6w (After irrigation and debridement)   V1 6 g + V2 0.8 g + BC 80 g                                                               Abnormal sound   32                   86            120       satisfied        failure

  11        Two-stage                                                16                                                            I.V. F 6w                                                                                I.V. F 4w                                                   V1 6 g + A1 0.6 g + BC 120 g                                                              None             48+18                90            90        satisfied        success

  12        Two-stage                                                24                                                            I.V. F 6w (Other institute treatment)                                                    I.V. F 6w + Oral F 6w                                       --                                                                                        None             25                   51            90        Not satisfied    success

  13        Debridement and Two-stage                                52                                                            I.V. F 6w + V1 6w + Oral F 6w                                                            I.V. F 4w + Oral F 8w + R 12w                               V1 10 g + A1 2.5 g+ BC 80 g                                                               None             64                   85            90        satisfied        success

  14        Two-stage                                                --                                                            I.V. F 4w + V1 4w + Oral I 8w                                                            I.V. F 4w + Oral I 8w (No reimplantation)                   F 4 weeks + V1 4w (Irrigation)                                                            None             118                  82            --        Not satisfied    failure

  15        Two-stage                                                12                                                            I.V. F 6w + Oral F 6w                                                                    I.V. F 4w                                                   V1 8 g + BC 80 g                                                                          None             75                   92            --        satisfied        success

  16        Double Two-stage First revision at outside institution   14                                                            I.V. F 6w + Oral F 6w                                                                    I.V. F 4w                                                   V1 12 g + BC 120 g                                                                        None             118                  87            --        satisfied        success

  17        Two-stage                                                18                                                            I.V. F 4w + Oral F 12w                                                                   I.V. F 4w                                                   V1 8 g + M 4 g +BC 80 g                                                                   Nerve injury     97                   86            --        satisfied        success

  18        Two-stage exchange spacer and prosthesis resection       72                                                            [\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}1: I.V. F 12w + A1 8w\               C1 6 weeks (Irrigation after spacer resection)              [\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}1: V1 12 g + BC 100 g\                None             71                   62            --        Not satisfied    failure
                                                                                                                                   [\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}2: I.V. V2 4w + L2 4w +Oral F 8w                                                                 [\#](#tfn2-medscimonit-24-5549){ref-type="table-fn"}2: V1 12 g + BC 100 g                                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\#1 -- first spacer to second spacer; \#2 -- second spacer to third spacer or reimplantation; \#3 -- third spacer to reimplantation. A~1~ -- Amphotericin B; A~2~ -- Amikacin; A~3~ -- Azithromycin; BC -- bone cement: (1 g gentamicin/40 g bone cement); C~1~ -- Caspofungin; C~2~ -- Ciprofloxacin; F -- fluconazole; I -- Itraconazole; L~1~ -- Levofloxacin; L~2~ -- Linezolid; M -- Meropenem; R -- rifampicin; V~1~ -- Vancomycin; V~2~ -- Voriconazole; 1^\*^ -- Peri-prostnesti fracture + Renal insufficiency + Leukopenia; "−" -- unknown.

###### 

The impact of debridement and irrigation history, McPherson classification, and infection type on the outcome.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                          Success (n=13)                                                  Failure (n=5)       Univariate analysis\
                                                                                                                                                                        P
  --------------------------------------------------------------------------------- --------------------------------------------------------------- ------------------- ----------------------
  Demographic data                                                                                                                                                      

   Age (range)                                                                      60.1 (42--78)                                                   64 (54--78)         0.462

   Sex (Male, %)                                                                    4 (30.8%)                                                       3 (60.0%)           0.326

   BMI (kg/m^2^)                                                                    23.8 (16.6--31.3)                                               26.9 (22.3--34.2)   0.204

  Prosthesis age (month)                                                            25 (1--84)                                                      10.7 (1--36)        0.223

  Interval between prosthesis resection and reimplantation(weeks)                   23.1 (12--40)                                                   69 (16--132)        0.240

  Antifungal agents in spacer[\*](#tfn3-medscimonit-24-5549){ref-type="table-fn"}   5 (41.6%)[\*](#tfn3-medscimonit-24-5549){ref-type="table-fn"}   3 (60.0%)           0.620

  Debridement history                                                               3 (23.1%)                                                       2 (40%)             0.583

  Mixed infection                                                                   6 (46.2%)                                                       4 (80.0%)           0.314

  Infection site (Hip)                                                              3 (23.1%)                                                       2 (40%)             0.583

  Sinus tract                                                                       3 (23.1%)                                                       2 (40%)             0.583

  Diabetes mellitus                                                                 2 (15.4%)                                                       2 (40%)             0.533

  Hypertension/heart disease                                                        5 (38.4%)                                                       2 (40%)             1.00

  Mcpherson grade                                                                                                                                                       

   Host B+C                                                                         2 (15.4%)                                                       2 (40%)             0.533

   Extremity 2                                                                      9 (69.2%)                                                       5 (100%)            0.278
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

One patient had the first operation in other institute, whether the spacer contained antifungal agents or not is unknown.

Therefore, in the success group, there were 5 joints that were mixed with antifungal agents in the spacer (41.6%, 5/12).
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